Citadel Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-19,600
| Closed | -$316K | – | 8417 |
|
|
2017
Q2 | $316K | Sell |
19,600
-11,800
| -38% | -$174K | ﹤0.01% | 5818 |
|
|
2017
Q1 | $397K | Buy |
+31,400
| New | +$379K | ﹤0.01% | 5427 |
|
|
2016
Q3 | – | Sell |
-8,000
| Closed | -$231K | – | 8112 |
|
|
2016
Q2 | $231K | Buy |
+8,000
| New | +$261K | ﹤0.01% | 5623 |
|
|
2016
Q1 | – | Sell |
-3,000
| Closed | -$128K | – | 8723 |
|
|
2015
Q4 | $128K | Buy |
3,000
+600
| +25% | +$24K | ﹤0.01% | 6409 |
|
|
2015
Q3 | $85K | Sell |
2,400
-3,700
| -61% | -$167K | ﹤0.01% | 7128 |
|
|
2015
Q2 | $280K | Buy |
6,100
+3,100
| +103% | +$147K | ﹤0.01% | 5850 |
|
|
2015
Q1 | $141K | Hold |
3,000
| – | – | ﹤0.01% | 6556 |
|
|
2014
Q4 | $95K | Sell |
3,000
-6,400
| -68% | -$187K | ﹤0.01% | 6685 |
|
|
2014
Q3 | $223K | Buy |
9,400
+3,800
| +68% | +$97.3K | ﹤0.01% | 5617 |
|
|
2014
Q2 | $168K | Buy |
5,600
+3,400
| +155% | +$91.7K | ﹤0.01% | 5752 |
|
|
2014
Q1 | $58K | Sell |
2,200
-17,200
| -89% | -$430K | ﹤0.01% | 6656 |
|
|
2013
Q4 | $488K | Buy |
19,400
+15,300
| +373% | +$341K | ﹤0.01% | 4056 |
|
|
2013
Q3 | $84K | Sell |
4,100
-5,900
| -59% | -$122K | ﹤0.01% | 5460 |
|
|
2013
Q2 | $200K | Buy |
+10,000
| New | +$178K | ﹤0.01% | 4672 |
|
Citadel Advisors's IPXL Position: Q2 2018 in Review
Citadel Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 21,316 shares — an estimated $415K sold.
Citadel Advisors first reported a position in IPXL in Q2 2013 and held it in 19 quarters. The position peaked at $35.2M in Q2 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Citadel Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Citadel Advisors sold 21,316 Impax Laboratories, Inc. shares in Q2 2018, an estimated $415K.
- Citadel Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 19 quarters.
- Citadel Advisors's Impax Laboratories, Inc. position peaked at $35.2M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.